Patients with hypertension-associated thrombotic microangiopathy may present with complement abnormalities

Kidney International

Volumn 91, Issue 6, 2017, Pages 1420-1425

  Timmermans, Sjoerd A M E G ^a   Abdul Hamid, Myrurgia A ^a   Vanderlocht, Joris ^a   Damoiseaux, Jan G M C ^a   Reutelingsperger, Chris P ^b   van Paassen, Pieter ^a   de Heer, F ^c   Krekels, M ^c   Stifft, F ^c   Verseput, G ^c   Boorsma, S ^c   Grave, W ^c   Huitema, J ^c   Wirtz, J ^c   ter Braak, N ^c   Frenken, L ^c   Gaertner, S ^c   Christiaans, M ^c   Fung, T ^c   Gelens, M ^c   Kooman, J ^c   Leunissen, K ^c   Litjens, E ^c   van der Net, J ^c   van der Sande, F ^c   van Duijnhoven, E ^c   more..

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NONE

Author keywords

atypical hemolytic uremic syndrome; complement dysregulation; genetics; malignant hypertension; thrombotic microangiopathy

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C5B; MEMBRANE COFACTOR PROTEIN; C3 PROTEIN, HUMAN; CD46 PROTEIN, HUMAN; CFI PROTEIN, HUMAN; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H, HUMAN; COMPLEMENT FACTOR I;

ADULT; AGED; ARTICLE; C3 GENE; CAPILLARY WALL; CD46 GENE; CFH GENE; CFI GENE; CLINICAL ARTICLE; COHORT ANALYSIS; COMPLEMENT DISORDER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; END STAGE RENAL DISEASE; FEMALE; GENE; GENETIC DISORDER; GLOMERULUS CAPILLARY; HAPLOTYPE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; IN VIVO STUDY; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SYMPTOM; THROMBOTIC THROMBOCYTOPENIC PURPURA; BIOPSY; BLOOD; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COMPLEMENT ACTIVATION; COMPLICATION; DISEASE EXACERBATION; DNA MUTATIONAL ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; KIDNEY; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; BIOPSY; BLOOD PRESSURE; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE COFACTOR PROTEIN; MUTATION; PHENOTYPE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; THROMBOTIC MICROANGIOPATHIES;

EID: 85011579203     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.12.009     Document Type: Article

References (35)

1. Zhang, B., Xing, C., Yu, X., et al. Renal thrombotic microangiopathies induced by severe hypertension. Hypertens Res 31 (2008), 479–483.
2. de Jorge, E.G., Macor, P., Paixao-Cavalcante, D., et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 22 (2011), 137–145.
3. Noris, M., Galbusera, M., Gastoldi, S., et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood 124 (2014), 1715–1726.
4. Noris, M., Caprioli, J., Bresin, E., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5 (2010), 1844–1859.
5. Maga, T.K., Nishimura, C.J., Weaver, A.E., et al. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat 31 (2010), E1445–E1460.
6. Sullivan, M., Rybicki, L.A., Winter, A., et al. Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet 75 (2011), 639–647.
7. Bresin, E., Daina, E., Noris, M., et al., for the International Registry of Recurrent and Familial HUS/TTP. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 1 (2006), 88–99.
8. Legendre, C.M., Licht, C., Muus, P., et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368 (2013), 2169–2181.
9. Licht, C., Greenbaum, L.A., Muus, P., et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87 (2015), 1061–1073.
10. Fakhouri, F., Hourmant, M., Campistol, J.M., et al. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68 (2016), 84–93.
11. Caprioli, J., Castelletti, F., Bucchioni, S., et al., for the International Registry of Recurrent and Familial HUS/TTP. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 12 (2003), 3385–3395.
12. Bresin, E., Rurali, E., Caprioli, J., et al., for the European Working Party on Complement Genetics in Renal Diseases. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 24 (2013), 475–486.
13. Reynolds, J.C., Agodoa, L.Y., Yuan, C.M., Abbott, K.C., Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 42 (2003), 1058–1068.
14. Bienaime, F., Dragon-Durey, M.A., Regnier, C.H., et al. Mutations in components of complement influence the outcome of factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77 (2010), 339–349.
15. Richards, A., Kemp, E.J., Liszewski, M.K., et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 100 (2003), 12966–12971.
16. Hakobyan, S., Tortajada, A., Harris, C.L., et al. Variant-specific quantification of factor H in plasma identifies null alleles associated with atypical hemolytic uremic syndrome. Kidney Int 78 (2010), 782–788.
17. Mohlin, F.C., Nilsson, S.C., Levart, T.K., et al. Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients. Mol Immunol 65 (2015), 367–376.
18. Roumenina, L.T., Frimat, M., Miller, E.C., et al. A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood 119 (2012), 4182–4191.
19. Yin, W., Ghebrehiwet, B., Weksler, B., Peerschke, E.I., Regulated complement deposition on the surface of human endothelial cells: effect of tobacco smoke and shear stress. Thromb Res 122 (2008), 221–228.
20. Cataland, S.R., Holers, V.M., Geyer, S., et al. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood 123 (2014), 3733–3738.
21. Volokhina, E.B., Westra, D., van der Velden, T.J., et al. Complement activation patterns in atypical haemolytic uraemic syndrome during acute phase and in remission. Clin Exp Immunol 181 (2015), 306–313.
22. Chua, J.S., Baelde, H.J., Zandbergen, M., et al. Complement factor C4d is a common denominator in thrombotic microangiopathy. J Am Soc Nephrol 26 (2015), 2239–2247.
23. Le Quintrec, M., Zuber, J., Moulin, B., et al. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant 13 (2013), 663–675.
24. Noris, M., Remuzzi, G., Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 22 (2013), 704–712.
25. Sallee, M., Ismail, K., Fakhouri, F., et al. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol, 14, 2013, 3.
26. Fakhouri, F., Roumenina, L., Provot, F., et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 21 (2010), 859–867.
27. Chobanian, A.V., Bakris, G.L., Black, H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003), 1206–1252.
28. van den Born, B.J., van der Hoeven, N.V., Groot, E., et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 51 (2008), 862–866.
29. van Paassen, P., van Breda Vriesman, P.J., van Rie, H., Tervaert, J.W., Signs and symptoms of thin basement membrane nephropathy: a prospective regional study on primary glomerular disease—The Limburg Renal Registry. Kidney Int 66 (2004), 909–913.
30. Westra, D., Volokhina, E., van der Heijden, E., et al. Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 25 (2010), 2195–2202.
31. Volokhina, E., Westra, D., Xue, X., et al. Novel C3 mutation p.Lys65Gln in aHUS affects complement factor H binding. Pediatr Nephrol 27 (2012), 1519–1524.
32. Maga, T.K., Meyer, N.C., Belsha, C., et al. A novel deletion in the RCA gene cluster causes atypical hemolytic uremic syndrome. Nephrol Dial Transplant 26 (2011), 739–741.
33. Dragon-Durey, M.A., Loirat, C., Cloarec, S., et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16 (2005), 555–563.
34. Yang, S., McGookey, M., Wang, Y., et al. Effect of blood sampling, processing, and storage on the measurement of complement activation biomarkers. Am J Clin Pathol 143 (2015), 558–565.
35. Seelen, M.A., Roos, A., Wieslander, J., et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 296 (2005), 187–198.